Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC.19 ▼AHA 2018 ▼Diabetes & CVD ▼Epigenetics in CVD ▼Expert Meeting GLP-1, CVD & T2DM ▼HFpEF: The essentials to know ▼Invest in your arteries ▼LDL-c & PCSK9i in Clinical Cardiology ▼PCSK9 ▼

HoFH

Feb. 8, 2014

Share this page with your colleagues and friends:

Continue reading:

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Antithrombotic regime with NOAC but no aspirin most favorable for patients with AF and ACS/PCI

News - Mar. 17, 2019

hsCRP levels at and after ACS associated with risk of recurrent MACE and death

Literature - Mar. 12, 2019 - Mani P et al., - JAMA Cardiol. 2019

Atherosclerosis

Lp(a) testing in an FH cascade screening program can identify individuals at high ASCVD risk

Literature - Mar. 6, 2019 - Ellis KL et al., - J Am Coll Cardiol. 2019

Diet with red meat as main protein source increases levels of TMAO, which is linked to atherogenesis

Literature - Feb. 19, 2019 - Wang Z et al., - Eur Heart J 2019

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019

Atrial fibrillation

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Antithrombotic regime with NOAC but no aspirin most favorable for patients with AF and ACS/PCI

News - Mar. 17, 2019

Proof-of-concept study shows 84% true AF in those with irregular puls detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

CV Inflammation

Prognostic value of IL-1β and a potential role of inflammation signaling in ADHF

Literature - Mar. 12, 2019 - Pascual-Figal DA et al. - JACC 2019

hsCRP levels at and after ACS associated with risk of recurrent MACE and death

Literature - Mar. 12, 2019 - Mani P et al., - JAMA Cardiol. 2019

Better oral hygiene behavior can positively modify the CV risks associated with poor oral health

Literature - Feb. 21, 2019 - Park S-Y et al,. - Eur Heart J. 2019

CVRM

Dose-response relationship between sedentary behavior and CVD in older women

Literature - Feb. 27, 2019 - Bellettiere J et al., - Circulation. 2019

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Diabetes

SGLT2 inhibitor treatment is beneficial in T2DM patients with a broad range of ejection fractions

News - Mar. 19, 2019

New ACC/AHA primary prevention guideline takes a patient-centered approach

News - Mar. 17, 2019

Host genetics influences gut microbiome composition, which affects glucose metabolism

Literature - Mar. 6, 2019 - Sanna S et al., - Nature Genetics 2019

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

Online-CME - This course consists of 4 separate lectures

Lp(a) testing in an FH cascade screening program can identify individuals at high ASCVD risk

Literature - Mar. 6, 2019 - Ellis KL et al., - J Am Coll Cardiol. 2019

Novel strategies to target PCSK9 in patients with hypercholesterolemia

Literature - Mar. 5, 2019 - Seidah NG et al. - Cardiovasc Res 2019

GLP-1 RA & CVD

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Heart Failure

Central and peripheral exercise-related factors independently associated with presence of HFpEF

Literature - Mar. 21, 2019 - Wolsk E et al. - JACC Heart Failure 2019

Echocardiographic predictors of clinical outcomes in patients with HF and severe secondary mitral regurgitation

News - Mar. 21, 2019

Early in-hospital initiation of ARNI after ADHF improves outcomes in HFrEF

News - Mar. 21, 2019

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA

Hypertension

Less brain damage with intensive BP-lowering in older hypertensives, but no effect on function

News - Mar. 20, 2019

Smokers with baseline SBP >144 mmHg may experience harm with intensive BP lowering

Literature - Mar. 12, 2019 - Scarpa J et al. - JAMA Netw Open 2019

Renal denervation can lower heart rate in unmedicated hypertensive patients

Literature - Mar. 11, 2019 - Böhm M et al., - Eur Heart J. 2019

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

LDL-c & PCSK9i in Clinical Cardiology

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Cholesterol synthesis inhibitor reduces LDL-c in high CV risk patients

News - Mar. 19, 2019

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Lipids

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

Online-CME - This course consists of 4 separate lectures

Lp(a) testing in an FH cascade screening program can identify individuals at high ASCVD risk

Literature - Mar. 6, 2019 - Ellis KL et al., - J Am Coll Cardiol. 2019

Lp(a)

Lp(a) testing in an FH cascade screening program can identify individuals at high ASCVD risk

Literature - Mar. 6, 2019 - Ellis KL et al., - J Am Coll Cardiol. 2019

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

Online-CME - This course consists of 4 separate lectures

Novel strategies to target PCSK9 in patients with hypercholesterolemia

Literature - Mar. 5, 2019 - Seidah NG et al. - Cardiovasc Res 2019

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

DOACs may reduce thromboembolic events in patients with mitral stenosis and AF

Literature - Mar. 13, 2019 - Kim JY et al. - JACC 2019

Better clinical outcomes with DOACs vs. warfarin in patients with NVAF and low body weight

Literature - Mar. 5, 2019 - Lee S-R et al. - JACC 2019

Diet drinks associated with increased risk of CV outcomes and all-cause mortality in postmenopausal women

Literature - Feb. 25, 2019 - Mossavar-Rahmani Y et al. - Stroke 2019

© 2006 - 2019 pace-cme.org - About